Epizyme announced today that the FDA has granted orphan drug designation to its EZH2-inhibitor tazemetostat for the treatment of adults with INI1-negative epithelioid sarcoma.
Dual checkpoint inhibition with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced an objective response rate of 16% in patients with heavily treated, unselected, metastatic sarcoma, according to findings from the phase II ALLIANCE A091401 trial.
Adjuvant radiotherapy was associated with improved survival for patients with non-retroperitoneal abdominal soft tissue sarcomas (NRA-STS), but the addition of chemotherapy did not confer a similar survival benefit.
Researchers at Istanbul University Institute of Oncology have concluded that patients with high-risk extremity soft tissue sarcoma have similar 3-year outcomes whether they are assigned to neoadjuvant sequential chemoradiotherapy or radiation alone.
Chemotherapy with doxorubicin and ifosfamide improved progression-free survival and tumor response compared with doxorubicin alone in soft tissue sarcoma, but the combination may be best suited for young, fit patients.
Chinese researchers have concluded that the oral VEGFR2 inhibitor apatinib demonstrated efficacy with tolerable toxicity in a small study of patients with stage IV sarcoma, according to results published in Oncotarget.
Researchers at MD Anderson Cancer Center believe that including clinical genomic profiling into sarcoma management could result in more precise diagnosis and subclassification of the disease.
Suzanne George, MD, discusses an exceptional responder to pembrolizumab in leiomyosarcoma and the significance of these findings for further immunotherapy advances in the field.
Researchers concluded that survivors of Ewing sarcoma are largely free of physical limitations and there is little apparent difference between survivors and healthy people in terms of mental health.
Douglas Levine, MD, discusses a recent study in uterine carcinosarcoma and early steps toward developing therapeutic regimens.